Meta-analysis of tripterygium wilfordii hook F in the immunosuppressive treatment of IgA nephropathy

Internal Medicine

Volumn 49, Issue 19, 2010, Pages 2049-2055

  Chen, Yi Zhi ^a,b   Gao, Qing ^c   Zhao, Xue Zhi ^b   Chen, Xiang Mei ^a   Zhang, Feng ^b   Chen, Jing ^b   Xu, Cheng Gang ^b   Sun, Lin Lin ^b   Mei, Chang Lin ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c XIAMEN UNIVERSITY   (China)

Author keywords

Drug therapy; Glomerulonephritis; IGA; Meta analysis; Tripterygium

Indexed keywords

BENAZEPRIL; ENALAPRIL; PREDNISONE; TRIPTERYGIUM WILFORDII EXTRACT; VALSARTAN;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; COUGHING; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; META ANALYSIS; NAUSEA AND VOMITING; PROTEINURIA; REMISSION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CHINA; DRUGS, CHINESE HERBAL; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME; TRIPTERYGIUM;

EID: 77958097164     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3704     Document Type: Article

References (31)

1. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 347: 738-748, 2002.
2. Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int 66: 920-923, 2004.
3. Zhou FD, Zhao MH, Zou WZ, Liu G, Wang HY. The changing spectrum of primary glomerular diseases within 15 years: A survey of 3331 patients in a single Chinese centre. Nephrol Dial Transplant 24: 870-876, 2009.
4. Wang H, Zhang L, Lv J. Prevention of the progression of chronic kidney disease: practice in China. Kidney Int Suppl S63-S67, 2005.
5. Xu G, Tu W, Jiang D, Xu C. Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis. Am J Nephrol 29: 362-367, 2009.
6. Cheng J, Zhang X, Zhang W, He Q, Tao X, Chen J. Efficacy and safety of glucocorticoids therapy for IgA nephropathy: A metaanalysis of randomized controlled trials. Am J Nephrol 30: 315-322, 2009.
7. Lou T, Wang C, Chen Z, et al. Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy. Nephrology (Carlton) 11: 113-116, 2006.
8. Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev CD003965, 2003.
9. Nolin L, Courteau M. Management of IgA nephropathy: evidencebased recommendations. Kidney Int Suppl 70: S56-S62, 1999.
10. Lipsky PE, Tao XL. A potential new treatment for rheumatoid arthritis: thunder god vine. Semin Arthritis Rheum 26: 713-723, 1997.
11. Tao X, Lipsky PE. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am 26: 29-50, viii, 2000.
12. Qiu D, Kao PN. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R D 4: 1-18, 2003.
13. Brinker AM, Ma J, Lipsky PE, Raskin I. Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 68: 732-766, 2007.
14. Tao X, Younger J, Fan FZ, Wang B, Lipsky PE. Benefit of an extract of Tripterygium wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 46: 1735-1743, 2002.
15. Goldbach-Mansky R, Wilson M, Fleischmann R, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med 151: 229-240, W249-W251, 2009.
16. Leishi L. Clinical study of Tripterygium wilfordii Hook in treating glomerulonephritis (author's transl). Zhonghua Nei Ke Za Zhi 20: 216-220, 1981 (in Chinese, Abstract in Chinese).
17. Li LS. Clinical and experimental studies on the effect of Tripterygium wilfordii Hook in the treatment of nephritis. Zhonghua Yi Xue Za Zhi 62: 581-585, 1982 (in Chinese, Abstract in Chinese).
18. Jiang X. Clinical observations on the use of the Chinese herb Tripterygium wilfordii Hook for the treatment of nephrotic syndrome. Pediatr Nephrol 8: 343-344, 1994.
19. Xu G, Tu W, Jiang D, Xu C. Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: a meta-analysis. Nephron Clin Pract 111: c223-c228, 2009.
20. Shen SJ, Hu ZX, Wang SM, Li QH. Effects of a combined regime of Tripterygium wilfordii glycosides and benazepril in treatment of IgA nephropathy. Zhong Guo Zhong Xi Yi Jie He Shen Bing Za Zhi 10: 154-155, 2009 (in Chinese, Abstract in Chinese).
21. Chen Y, Qin Y. Clinical effects of triple therapy in treatment of IgA nephropathy patients with moderate proteinuria. Xian Dai Yi Yao Wei Sheng 25: 1645-1646, 2009 (in Chinese, Abstract in Chinese).
22. Yang FY, Wei CY, Li CY. A controlled study on Tripterygium wilfordii glycosides for treating IgA nephropathy patients who presented non-nephrotic syndrome. Zhong Hua Quan Ke Yi Xue 6: 1138-1139, 2008 (in Chinese, Abstract in English).
23. Ada LT, Su JH, Wang ZC. Clinical random control observation of 18 cases of the patient with syndrome of primary IgA nephropathy to be treated by tablet Tripterygium glocosides. Dang Dai Yi Xue 15: 12-13, 2008 (in Chinese, Abstract in English).
24. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions. updated September 2008 ed. Higgins JPT, Green S, Eds. John Wiley & Sons, Ltd., West Sussex, 2008: 8.1-8.50.
25. Zheng CX, Chen ZH, Zeng CH, Qin WS, Li LS, Liu ZH. Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney Int 74: 596-612, 2008.
26. Ohashi N, Katsurada A, Miyata K, et al. Role of activated intrarenal reactive oxygen species and renin-angiotensin system in IgA nephropathy model mice. Clin Exp Pharmacol Physiol 36: 750-755, 2009.
27. Mattii L, Segnani C, Cupisti A, et al. Kidney expression of RhoA, TGF-beta1, and fibronectin in human IgA nephropathy. Nephron Exp Nephrol 101: e16-e23, 2005.
28. Lai KN, Tang SC, Guh JY, et al. Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the renin-angiotensin system. J Am Soc Nephrol 14: 3127-3137, 2003.
29. Ihm CG, Jeong KW, Lee SH, Lee TW, Park JK. Effects of therapeutic agents on the inflammatory and fibrogenic factors in IgA nephropathy. Nephrology (Carlton) 12 (Suppl 3): S25-S26, 2007.
30. Wan Y, Gu L, Suzuki K, et al. Multi-glycoside of Tripterygium wilfordii Hook f. ameliorates proteinuria and acute mesangial injury induced by anti-Thy1.1 monoclonal antibody. Nephron Exp Nephrol 99: e121-e129, 2005.
31. Wan Y, Sun W, Zhang H, et al. Multi-Glycoside of Tripterygium wilfordii Hook f. Ameliorates Prolonged Mesangial Lesions in Experimental Progressive Glomerulonephritis. Nephron Exp Nephrol 114: e7-e14, 2009.